v3.25.0.1
Income Taxes
 12 Months Ended
Jan. 31, 2025
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of the net income before the provision for income taxes were as follows:
 Year Ended January 31,
 202520242023
 (in thousands)
Domestic$1,238,452 $792,495 $196,224 
Foreign77,132 39,817 53,052 
Total$1,315,584 $832,312 $249,276 
The provision for income taxes was as follows:
 Year Ended January 31,
 202520242023
 (in thousands)
Current:
Federal$323,625 $257,913 $254,505 
State52,186 44,457 33,548 
Foreign20,086 9,159 18,473 
Total current income tax expense
395,897 311,529 306,526 
Deferred:
Federal(78,476)(88,110)(173,941)
State(12,875)(20,201)16,673 
Foreign800 (8,368)(3,693)
Total deferred income tax expense
(90,551)(116,679)(160,961)
Total provision for income taxes
$305,346 $194,850 $145,565 
The provision for income taxes differs from the amount computed by applying the statutory federal tax rate as follows:
 Year Ended January 31,
 202520242023
 (in thousands, except percentages)
Tax at federal statutory rate$276,270 $174,785 $52,277 
State taxes56,336 37,137 13,666 
Foreign rate differential141 2,943 1,017 
Non-deductible compensation15,757 10,639 10,231 
Stock-based compensation58,770 96,936 124,631 
Permanent items
10,371 4,016 9,090 
Foreign-derived intangible income deduction(56,630)(63,571)(76,686)
Research and development credits(49,813)(39,226)(38,127)
Tax uncertainties7,478 2,674 2,296 
Change in valuation allowance(7,765)(14,109)39,288 
Deferred rate change(3,993)(6,803)2,014 
Other(1,576)(10,571)5,868 
Total$305,346 $194,850 $145,565 
Effective tax rate23.2 %23.4 %58.4 %
Deferred income taxes result from differences in the recognition of amounts for tax and financial reporting purposes, as well as operating loss and tax credit carryforwards. Significant components of our deferred income tax assets as of January 31, 2025 and 2024 are as follows:
 
As of January 31,
 20252024
 (in thousands)
Deferred tax assets:
Net operating loss carryforwards$7,362 $12,995 
Research and development credit carryforwards6,586 16,610 
Stock-based compensation59,565 84,906 
Accruals and reserves43,953 39,295 
Deferred revenue328,114 308,152 
Capitalized research expenditures514,667 379,102 
Operating lease liabilities16,551 17,829 
Other assets
2,957 4,105 
Total deferred tax assets979,755 862,994 
Valuation allowance(28,990)(35,949)
Total deferred tax assets net of valuation allowance950,765 827,045 
Deferred tax liabilities:
Property and equipment and intangible assets(38,343)(35,007)
Deferred contract acquisition costs(76,439)(83,862)
Operating right-of-use assets(14,233)(14,396)
Strategic investments
(75,290)(35,480)
Total deferred tax liabilities(204,305)(168,745)
Net deferred tax assets$746,460 $658,300 
The realization of tax benefits of net deferred tax assets is dependent upon future levels of taxable income, of an appropriate character, in the periods the items are expected to be deductible or taxable. Based on the available objective evidence during the year ended January 31, 2025, we believe that it is more likely than not that the tax benefits relating to U.S. losses that are capital in nature and certain state deferred tax assets may not be realized prior to expiration. Accordingly, we have maintained a valuation allowance against these deferred tax assets and intend to maintain the applicable valuation allowance until sufficient positive evidence exists to support a reversal of, or decrease in, the valuation allowance.
As of January 31, 2025, we had net operating loss carryforwards of approximately $1.8 million for federal income tax purposes, and $12.5 million for state income tax purposes, which will begin to expire in the year 2033 if unused. We also had certain foreign net operating loss carryforwards of $22.4 million, which have an indefinite life.
As of January 31, 2025, we also had research and development credit carryforwards of approximately $1.2 million for federal income tax purposes and $23.4 million for state income tax purposes. The federal research and development tax credits have a twenty-year carryover period while the state research and development tax credits carry forward indefinitely.
We indefinitely reinvest earnings from our foreign subsidiaries and therefore no deferred tax liability has been recognized on the basis difference created by such earnings. We have not provided foreign withholding taxes for any undistributed earnings of our foreign subsidiaries.
A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:
Unrecognized Tax Benefits (in thousands)Year Ended January 31,
 202520242023
   
Balance, beginning of year$41,772 $30,404 $19,171 
Tax Positions taken in prior year:
Gross increases931 228 877 
Gross decreases— — — 
Tax Positions taken in current year:
Gross increases13,650 12,415 10,547 
Gross decreases(19)(891)— 
Lapse of Statute of Limitations— (384)(191)
Acquisitions— — — 
Balance, end of year$56,334 $41,772 $30,404 
As of January 31, 2025, gross unrecognized tax benefits related to uncertain tax positions were $56.3 million ($66.0 million total, including $9.7 million associated with interest and penalties). As of January 31, 2024, gross unrecognized tax benefits related to uncertain tax positions were $41.8 million ($46.5 million total, including $4.7 million associated with interest and penalties). As of January 31, 2023, gross unrecognized tax benefits related to uncertain tax positions were $30.4 million ($32.5 million total, including $1.6 million associated with interest and penalties). We recognized approximately $9.7 million, $4.7 million, and $1.6 million in potential interest and penalties associated with uncertain tax positions during fiscal years ended January 31, 2025, 2024, and 2023, respectively. To the extent taxes are not assessed with respect to uncertain tax positions, substantially all amounts accrued (including interest and penalties) will be reduced and reflected as a reduction of the overall income tax provision. Unrecognized tax benefits and associated accrued interest and penalties are included in our income tax provision.
We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and various foreign jurisdictions. As of January 31, 2025, all of the years in which net operating losses or tax credits were utilized remain open to examination by the federal and state tax authorities. We believe that an adequate provision has been made for any adjustments that may result from tax examinations. Although the timing of the resolution, settlement, and closure of audits is not certain, we do not believe it is reasonably possible that our unrecognized tax benefits will materially change in the next 12 months.
As required by the 2017 Tax Cuts and Jobs Act, we started capitalizing research and development expenses incurred beginning in fiscal year 2023. These expenses are capitalized and amortized over five years for domestic research and fifteen years for international research. The mandatory capitalization requirement increases our cash tax liabilities but also decreases our effective tax rate due to increasing the foreign-derived intangible income deduction. The cash flow impact will decrease over time as capitalized research and development expenditures continue to amortize.